低分子肝素对慢性阻塞性肺疾病大鼠模型细胞间黏附分子-1、单核细胞趋化蛋白-1表达的影响
|
摘要
目的观察低分子肝素(LMWH)对慢性阻塞性肺疾病(COPD)大鼠模型肺组织细胞间黏附分子-1(ICAM-1)和单核细胞趋化蛋白-1(MCP-1)表达的影响,探讨其对COPD可能的干预机制。
方法将Wistar大鼠30只随机分为三组：①健康对照组(n=10)：正常喂养40天,不做任何干预；②COPD模型组(n=10)：采用熏吸香烟加气管内注入脂多糖的方法建立COPD大鼠模型；③LMWH干预组(n=10)：模型制备同前,熏烟前半小时皮下注射LMWH150u/kg,每天1次。观察各组肺组织病理改变、血气指标、肺泡灌洗液(BALF)的细胞计数及分类,应用免疫组化法测定肺组织ICAM-1、MCP-1的表达情况。
结果所建COPD大鼠模型的病理学改变符合人类COPD的特点。①与健康对照组比较,COPD模型组肺组织ICAM-1、MCP-1的表达增强(P<0.01),且ICAM-1与BALF中中性粒细胞数成正比(r=0.82,t=4.00,P<0.01),MCP-1与BALF中巨噬细胞数成正比(r=0.81,t=3.96,P<0.01)。②与COPD模型组比较,LMWH干预组肺组织的病理改变轻,BALF中白细胞总数、中性粒细胞数百分比下降(P<0.01),肺组织ICAM-1、MCP-1的表达减弱(P<0.05、0.01)。
结论ICAM-1、MCP-1参与气道炎症的发生,LMWH可能通过抑制ICAM-1、MCP-1表达而减轻COPD气道炎症。
Objective To observe the effect of low molecular weight heparin(LMWH) on expression of intercellular adhesion molecular-1(ICAM-1) and monocyte chemoattractant protein-1(MCP-1) in lung tissue of rats with chronic obstructive pulmonary disease(COPD), then demonstrate the intervention mechanism for chronic obstructive pulmonary disease of low molecular weight heparin.
Methods Thirty Wistar rats were randomly divided into three groups,with 10 in each:①normal control group:raised the rats in normal condition for forty days without any interferende;②COPD model group:The COPD model was established by intratracheal instillation of lipopolysaccharide and exposed to cigarette smoking;③LMWH treated group:model methods were the same as above, LMWH 150U/kg was given by hypodermic injection,daily, Pathologic changes of the lung tissue,blood gas and the total and differential cell counts of bronchoalveolar lavage fluid were determined.The expression of ICAM-1 and MCP-1 was observed by immunohistochemical method.
.Results The pathological changes in COPD model group was coincident with that in humans.①Compared with normal control group, The expression of ICAM-1、MCP-1 of lung tissue of the COPD group significantly increased (P<0.05), and ICAM-1 was positively correlated with the leukocyte numbers and neutrophils in BALF in the model group(r=0.82,t=4.00,P<0.01),MCP-1 was positively correlated with the macrophage in BALF in the model group(r=0.81, t=3.96,P<0.01);②Compared with COPD model group,pathological changes of the lung tissue in LMWH treated group decreased.The total white blood cells and the percentages of neutrophils in BALF in LMWH treated group decreased (P<0.01).The expression of ICAM-1 and MCP-1 in LMWH treated group decreased (P<0.05、0.01)
Conclusion:ICAM-1 and MCP-1 may be involved in the process of airway inflammation in COPD.LMWH may decrease the expression of ICAM-1 and MCP-1 to relievate the inflammatory reaction.
方法将Wistar大鼠30只随机分为三组：①健康对照组(n=10)：正常喂养40天,不做任何干预；②COPD模型组(n=10)：采用熏吸香烟加气管内注入脂多糖的方法建立COPD大鼠模型；③LMWH干预组(n=10)：模型制备同前,熏烟前半小时皮下注射LMWH150u/kg,每天1次。观察各组肺组织病理改变、血气指标、肺泡灌洗液(BALF)的细胞计数及分类,应用免疫组化法测定肺组织ICAM-1、MCP-1的表达情况。
结果所建COPD大鼠模型的病理学改变符合人类COPD的特点。①与健康对照组比较,COPD模型组肺组织ICAM-1、MCP-1的表达增强(P<0.01),且ICAM-1与BALF中中性粒细胞数成正比(r=0.82,t=4.00,P<0.01),MCP-1与BALF中巨噬细胞数成正比(r=0.81,t=3.96,P<0.01)。②与COPD模型组比较,LMWH干预组肺组织的病理改变轻,BALF中白细胞总数、中性粒细胞数百分比下降(P<0.01),肺组织ICAM-1、MCP-1的表达减弱(P<0.05、0.01)。
结论ICAM-1、MCP-1参与气道炎症的发生,LMWH可能通过抑制ICAM-1、MCP-1表达而减轻COPD气道炎症。
Objective To observe the effect of low molecular weight heparin(LMWH) on expression of intercellular adhesion molecular-1(ICAM-1) and monocyte chemoattractant protein-1(MCP-1) in lung tissue of rats with chronic obstructive pulmonary disease(COPD), then demonstrate the intervention mechanism for chronic obstructive pulmonary disease of low molecular weight heparin.
Methods Thirty Wistar rats were randomly divided into three groups,with 10 in each:①normal control group:raised the rats in normal condition for forty days without any interferende;②COPD model group:The COPD model was established by intratracheal instillation of lipopolysaccharide and exposed to cigarette smoking;③LMWH treated group:model methods were the same as above, LMWH 150U/kg was given by hypodermic injection,daily, Pathologic changes of the lung tissue,blood gas and the total and differential cell counts of bronchoalveolar lavage fluid were determined.The expression of ICAM-1 and MCP-1 was observed by immunohistochemical method.
.Results The pathological changes in COPD model group was coincident with that in humans.①Compared with normal control group, The expression of ICAM-1、MCP-1 of lung tissue of the COPD group significantly increased (P<0.05), and ICAM-1 was positively correlated with the leukocyte numbers and neutrophils in BALF in the model group(r=0.82,t=4.00,P<0.01),MCP-1 was positively correlated with the macrophage in BALF in the model group(r=0.81, t=3.96,P<0.01);②Compared with COPD model group,pathological changes of the lung tissue in LMWH treated group decreased.The total white blood cells and the percentages of neutrophils in BALF in LMWH treated group decreased (P<0.01).The expression of ICAM-1 and MCP-1 in LMWH treated group decreased (P<0.05、0.01)
Conclusion:ICAM-1 and MCP-1 may be involved in the process of airway inflammation in COPD.LMWH may decrease the expression of ICAM-1 and MCP-1 to relievate the inflammatory reaction.
引文
[1]Pauwels RA, Buist AS, Calverley, et al. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBL/WHO Global intiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. AM J Respir Crit Care Med,2001,163,1256-1276
[2]陈丕仁,崔力,候加法,等.慢性阻塞性肺病动物模型的研究进展[J].中国实验动物学报,2007,15(3)：238-242
[3]Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic of obstructive pulmonary disease (COPD) [J].Eur Respir,1995,8:1398-1420
[4]Setoguchi Y, Tamaki Y, Oki M, et al. Transfer of endothelial nitric oxide synthase gene in the purpose of gene therpy. Nippon Rinsho,1996,54:369-376
[5]Janssens SP, Shimouchi A, Quetermous T, et al. Cloning and expression of a cDNA encoding human endothelial-derived relaxing factor/nitric oxide synthase. J Biol Chem,1992,267:14519-14522
[6]Boughton-Smith NK, Hutcheson IR, Deakin AM, et al. Protective effect of S-nitroso-N-acetyl-peniillamine in endotoxin-induced acute intestinal damage in the rats. EUR J Pharmacol.1990, Dec 4,191(3):484-488
[7]Chu A, Chsmbers DE, Lin CC, et al. Effects of inhibition of nitric oxide formation on basal vasomotion and endothelium-dependent responses of coronary arteries in awake dog. J Clin Invest,1991, Jun,87:1964-1968
[8]Bassenge E, ric Antiplatelet effects of endotheliud-deried relaxing factor and nitric oxide donors. Eur Heart J,1991,12
[9]Blau h,Riklis S,Vanlarden JF, et al. Nitric oxide production by ratalveolar macrophages can be modulated invitro by surfanctant protein A. Am Jphsiol,1997,292(6): 1198-1204
[10]Wright JL,Churg A. Animal models of cigarette smoke-induced COPD[J]. Chest,2002, 122:301-306.
[11]金焱,庞宝森,武维屏,等.一种实验性大鼠慢性阻塞性肺疾病模型的建立.心肺血管病杂志,2004,239(3)：179-181
[12]马楠,崔德建,梁延杰,等.气管内注入脂多糖法建立大鼠慢性支气管炎模型.中华结核和呼吸杂志,1996,22(6)：371-372
[13]宋一平,崔德健,茅培英,等.慢性阻塞性肺病大鼠模型的建立及药物干预的影响[J].军医进修学院学报,2001,22：99-102
[14]Tavares JL, Wangoo A, Dilworth P, et al.Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages[J]. Respir Med,1997,91:31-39.
[15]Brosnan CF, Cannella B, Battbtini L, et al. Cytokine localization in multiple sclerosis lesions:correlation with adhesion molecule expression and reactive nitrogen species[J]. Neurology,2005,45(6):S1-S21.
[16]S0, Novotny JR, Wicks IP, et al.The role of the LFA-1 ICAM-1 interaction in human leukocyte homing and adhesion.Immunol Rev,1989,108:135
[17]Tosi MF, Stark JM, Smith CW, et al. Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines:Effects on neutrophil epithelial cell adhesion[J].Am J Respir Cell Mol Biol,1992,7:214-221
[18]Vignola AM, Campbell AM, Chanez P, et al. HLA-DR an d ICAM-1 expression on bronchial epithelial cells in asthma and chronic bronchitis [J]. Am Rev Respir Dis,1993; 148(3): 689.
[19]Stefano AD, Maestrelli P, Roggeri A, et al. Upregulat ion of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis [J]. Am J Respir Crit Care Med,1994;149(3):803.
[20]曾春芳,吴亚梅.细胞粘附分子在慢性阻塞性肺疾病大鼠气道炎症中的作用[J],重庆医科大学学报,2004,29(5)：644-647
[21]Steve K, Springer T, Schmalstieg F, et al. Defective Natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency[J].J Immunol,1984,133:2972-2980
[22]HACIEVLIYAGIL SS, GUNEN H,MUTLU LC, et al. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease[J]. RespirMed,2006,100(5):846-54
[23]RAHMAN MS, YANG J, LIAN YS, et al. IL-17R activation of human airway smooth muscle cells induces CXCL-8 production via a transcrip tional-dependent mechanism. Clinical Immunology[J],2005,115(1):268-276
[24]Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med,1998,338:436-445
[25]Masubuchi T, Koyama S, Sato E, et al. Smoke extract stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Pathol,1998,153:1903-1912.
[26]Gunn MD, Nelken NA, Liao X, et al. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgeniec mice but requires an additional stimulus for inflammatory activation. J Immunol,1997,158:376-383
[27]Hautamaki RD, Kobayashi DK, Senior RM, et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science,1997,277:2002-2004
[28]Traves SL, Culpltt SV. Russell RE, et al. Increased levels of the chemokines GRO alpha and MCP-1 in sputum samples from patients with COPD. Thorax,2002; 57(7):590.
[29]王慧,程德云,关键,等.单核细胞趋化蛋白—1与COPD大鼠气道炎症的研究[J].四川大学学报,2004,35(5)：634-637
[30]Zhang K, Mehrnaz GK, Michael LT, et al. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-indueed pulmonary fibrosis. J Immunol,1994,153; 4733-4741
[31]Chowers Y, Lider 0, Schor H, et al. Charaterization of protein of Z-dependent protease inhibitor[J]. Blood,2000,96:3049-3051
[32]Dowing LJ,Strieter RM, Kadell AM, et al. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis[J].Jvasc Surg,1998,28(5):848-854
[33]Lever R, Hoult JR, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro[J].Br J Pharmacol,2000,129(3):533-540
[34]Wan MX, Zhang XW, Torkvist L, et al. Low molecular weight hearin inhibits tumor necrosis factor alphainduced leukocyte rolling[J]. Inflamm Res,2001,50(12):581-584
[35]Deventer S JH. Tumor necrosis factor and Crohn's disease [J].Gut 1997,40:443-448
[36]韩红,夏冰,刘君炎.低分子肝素对三硝基苯磺酸诱发大鼠结肠炎肿瘤坏死因子α、CD62P的影响[J].中华消化杂志,2003,23(7)：418-420
[37]Manduteanu I.Voinea M, Capraru M, et al.A novel attribute of enxaparin:inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules[J]. Pharmacology.2002,65(1):32-37
[38]韩秀珍,焦波,尚雪原,等.低分子肝素对白细胞粘附和粘附分子表达的影响[J].中国生化药物杂志,2003,24(4)：179-181
[39]Jones H, Paul W, Page CP. The efects of heparin and related molecules on vascular pemeability and neutrophil accumulation in rabbit skin[J]. Br J Humncol,2002,135(2): 469-479
[40]李介秋,张开诚,吕新生,等.低分子量肝素治疗急性出血坏死性胰腺炎的实验研究[J].国普通外科杂志,2000,9(3)：234-236.
[41]张估,贻璞,李美花,等.低分子肝素对肾小球系膜细胞及细胞外基质作用的研究[J].中华肾脏病杂志,2001,17(1)：27-30.
[42]刘雷,孟建中.细胞间黏附分子-1在移植肾缺血再灌注损伤中的作用[J].国际移植与血液净化杂志,2006,4(2)12-14
[43]宋一平,崔德健,茅培英,等.慢性阻塞性肺病大鼠模型的建立及药物干预的影响[J].军医进修学院学报,2001,22：99-102
[44]程兆忠,徐晟伟,韩伟忠.氨溴索对慢性阻塞性肺疾病大鼠模型肺的保护作用[J].青岛大学医学院学报,2004,40(2)：101-106
[45]RACHEL A,BROWN, LUIGI A. Additional clinical benefit of enoxaparin in COPD patients receiving Salmeterol and fluticasone propionate in combination[ J]. Pulmonary Pharmacology Theraperties,2006,19(6):419-424
[1]GOLD Executive Committee[DB/OL]. Guidelines:Global Strategy for Diagnosis, Management, andr Prevention of COPD, Noverber2006[2006-11-18].
[2]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版).中华结核和呼吸杂志.2007,30：7-16
[3]程显声,李景周,张珍祥,等.慢性阻塞性肺疾病、肺心病人群防治的研究基线资料分析.中华结核和呼吸杂志,1998,121：749-752
[4]Stolk J. Rodolphus A, Dasies el al. [J] Pathol,1992,349-356
[5]Meshi B, Vitalis TZ, Ionescu D, et al. Emphysematous lung destruction by cigarette smoke The effects of latent adenoviral infection on the lung inflammatiory response [J]Am J Respir Cell M-ol Biol,2002,26(1):52-57.
[6]Retamales I, Elliot WM, Meshi B, et al. Ampification inflammation in Emphysema and its association with latent adenoviral infection [J].Am J Respir Crit Care Med,2001,164:469-473.
[7]Hertzen LCV. Chlamydia Pneumoniae and its role in chronic obstructive Pulmonary disease [J].Ann Med.1998,30:27-37.
[8]马楠.粘附分子及细胞因子在慢性阻塞性肺疾病中的作用[J].国外医学呼吸系统分册,1998,18：57-5
[9]Di Stefano A, Capelli A, lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med,1998, 158:1277-1285
[10]Majo J, Ghezzo H, Cosia MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J,2001,17:946-953.
[11]Jeffrey PK. Structural and inflammatory changes in COPD:a comparison with asthma Thorax,1998,53:129-136
[12]Finkelstein R. Fraser RS, Ghezzo H, et al. Alveolar inflammtion and its relationship to emphysema in smokers. Am J Respir Crit Care Med.1995,152:1666-1672
[13]Selman M, Montano M. Ramos L, et al. Tobaccosmoke induced lung emphysema. Am J Physiol,1996,211:734-743
[14]Finlay GA. O Driscoll LR. Russetl KJ. et al. Matrix metalloproteinase ex-pression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med,1997.156: 240-247
[15]Huninghake GW.Crystal RG Cigarette smoking and lung destruction:accumulation of neutrophils in the lung of cigarette smokers. Am Rev Respir Dis,1983,128:833-838
[16]Martin TR, Ganesh R. Manunder RJ, et al. The effects of chonic bronchitis and chronic air flow obstruction on lung cell populations recovered by bronchoalveolar lavage. Am Rev Respir Dis.1985,135:254-260
[17]Huinghake GW, Gadek JE, Kawanami 0, et al. Inflammatory and immune process in the human lung in health and disease evaluation by bronchoaveolar lavage. Am J Pathol,1979,97:149-206
[18]Lourdes SV. Annie P. Miguel G, et al. Up regulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell in COPD. Chest.2000.117:684-693
[19]Angshu B, Terence A R Seemungal. Raymond J Sapsford. et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations、 Thorax,2000,55:11-120
[20]Pi Stefawo A. Capelli A. Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med,1998,158:1277-1285
[21]Turato G, Zuin R, Saetta M. Pathogenesis and pathology of COPD. Respiration,2001, 68:117-128
[22]Zeid NA, Muller HK. Tobacco smoke induced lung granulomas and tumors:association with pulmonary langerhans cells. Pathology,1995, Z7:247-254
[23]D Hulst AI,Vermeulen KY,Brusselle GG,et al.Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J,2005,26:204-213
[23]Patel IS, Roberts NJ, Lloyd-Owen SJ, et al. Airway epithelial inflammatory responses and clinical parameters in COPD. Eur Respir J,2003,22:94-99
[24]Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med,1996,153:530-534
[25]W outers EF. Locgl and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc,2005,2:26-33
[26]Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbatIons [J]. Thorax,2000,55(2): 114-120
[27]Beeh KM, Kornmann O, Buhl R, et al. Neutrophil chemotactic activity of sputum from patients with COPD:role of interleukin 8 and leukotriene B4. Chest,2003,123:1240-1247.
[28]de Boer WI, Sont JK, van Schadewijk A, et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol,2000,190:619-626
[29]HACIEVLIYAGIL SS,GUNEN H,MUTLU LC, et al. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease[J]. RespirMed,2006,100(5):846-54
[30]RAHMAN MS, YANG J, LIAN YS, et al. IL-17R activation of human airway smooth muscle cells induces CXCL-8 production via a transcrip tional-dependent mechanism. Clinical Immunology[J],2005,115(1):268-276
[31]Sandford AJ, Chagani T, Weir TD, et al. Susceptibility genes for rapid deline of lung function in the lung heath study. AM j Respir Cric Care Med,2001, 163(2):469-473
[32]揭志军,杨文兰,蔡映云.α1-抗胰蛋白酶临床应用的前景.国外医学呼吸系统分册,1999,19(4)：192
[33]Kasielski M, Nowak D. Longterm administration of Nacetylcystinedecreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease [J]. Respir Med,2001,95:448-456
[34]Macnee W, Donaldson K. Exacerbations of COPD:environmental mechanisms. Chest, 2000;117:303s-317s
[35]Rahman I, M ulier B, Gilm our PS, et al. Oxidant-mediated lung epithelial cell tolerance:the role of intracellular glutathione and nuclear factor-kappaB. Biochem pharma,2001;62:787-794
[36]SHI M M, Chong I, Godleski JJ, et al. Regulation of macrophage inflammatory protein-2 gene expression by oxidative stress in rat alveolar macrophages. Im munology,1999; 97:309-315
[37]Salvatore C, Emanuela M, Laura D, et al. Protective effects of N-acetylcysteine on lung injury and red blood cell modification induced by carrageenan in the rat. FASEB J,2001;15:1187-1200
[38]Blames J, Beeklake M, Blanc P, et al. American thoracic society statement:occupational contribution to burden of airway disease. Am J Respir Crit Care Med,2003,167:787-797
[39]张嫒.吸入糖皮质激素和长效B2受体激动剂治疗支气管哮喘及慢性阻塞性肺疾病[J].临床荟萃,2005,20(6)：357-359
[40]Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapyimproves outcomes of exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004 69:1298-1303
[41]Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oralprednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med,2003,348:2618-2625
[42]Ohbayashi H. Novel neutrophil elastase inhibitors as a t reatment for neut rophil-predominant inflammatory lung diseases. Drugs,2002,5 (9):910-923
[43]Kuraki T, Ishibashi M, Takayama M, et al. A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rat s. Am J Respir Crit Care Med,2002,166 (4):496-500
[44]Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage mediated elastolysis roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol,2002,283 (4):L867-873
[45]Barnett WE. Improved anticoagulant substance[P]. WO 81/03276.1981
[46]Bianchini P. Process for preparation of oligosaccharide fractions by degradation of heparin[P]. US 4629699,1986.
[47]Nielson JI. Process of using tight absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin[P]. US 5106734,1992.
[48]Sundaram M, Qi Y, Shriver Z, et al. Rational design of low molecular weight heparins with improved in vivo activity[J]. PNAS,2003,100:651-656
[49]Bergonzini G. Oligo-Heparin Action on Endogenous Glycosaminoglycans. Pharmacokinetics:Direct and Mediated Effects[J]. Semin Thromb Hemost,1994,20(3):274.
[50]曹苹,张麟生.低分子肝素的抗凝与抗血栓作用[J].中国医院药学杂志,2001,21(5)：91.
[51]林平,林英,王晓红.低分子肝素[J].临床军医杂志,2006,34(5)：630-632
[52]Dowing LJ,Strieter RM,Kadell AM, et al. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis[J]. Jvasc Surg,1998,28(5):848-854
[53]韩秀珍,焦波,尚雪原,等.低分子肝素对白细胞粘附和粘附分子表达的影响[J].中国生化药物杂志,2003,24(4)：179-181
[54]Manduteanu I, Voinea M, Capraru M, et al.A novel attribute of enxaparin:inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules[J].Pharmacology.2002,65(1):32-37
[55]Mcbride WT, Armstrong MA, Mcmurray TJ. An investigation of the efectsHeparin, low molecular weight heparin, protamine, and fentany on the balance of pro-and anti-inflammatory cytoinesin in-vitro monocyte culturesl[J]. Anaesthesia,1996,51:635-640
[56]张佶,张贻璞,李美花,等.低分子肝素对肾小球系膜细胞及细胞外机制作用的研究[J].中华肾脏杂志,2001.17：27-29
[57]Gambaro G, Cavzzana A D. Luzi P, et al. Glylosaminoglycans morphological renal alterations and albuminuria in diabetic rats [J]. Kidney Int,1992,42:285-287
[58]Pross M, Lippert H, Nester G, et al. Effect of low molecular weight heparin on intra-abdominal metastasis in a lapavoscopic experinental study[J]. Int J Colorectal Dis,2004,19:143-146
[59]汪昱,郑起,闰均,等.低分子肝素对肝癌生长和转移抑制作用的研究[J].中华普通外科杂志,2004,19：758-760
[60]Deeps P R, Varalakshmi P. Protective efects of certopar in sodium, a low molecular weight heparin derivative, inexperimental atherosclerosis[J]. Clinchim Acta,2004, 339:105-115
[61]se Pattems of Low-Molecular Weight Heparin and the Impact on Length of Stay in Patients Hospitalized for Atrial Fibrillation。Am Heart J 145 (4):665-669,2003
[62]叶妮,张临洪.低分子肝素的药理作用及其在缺血性脑卒中的临床应用.国外医学-脑血管疾病分册.2001,9(1)：45-48
[63]吴蕙民,等.低分子肝索治疗进展型缺血性脑卒中(脑血栓)的临床研究.浙江临床医学,2001,3(1)17-18
[64]薛玉文,王均玲,杜以明,等.肝素与低分子肝素对急性肺栓塞抗凝治疗作用的比较.新医学,2005,36(3)：149-150
[65]杜鹃.慢性肺心病患者血浆α—颗粒膜蛋白及D—二聚体的变化.贵州医药,2001,25：401-402
[66]NenciGG, Berrettini M, Todiso T, Parise P. Enhanced plasma beta-thrombobloolobulin in hypoxaemia:effects of dipyridamole. N Engl J Med 1981(letter),304:1044
[67]Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Corsova C, and Chronic Obstructive bronchitis Hasemostasis G roup. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Haemost 1994,72:343-446
[68]马瑞,王少媛.慢性阻塞性肺疾病和慢性肺心病的血栓前状态研究[J].中华结核和呼吸杂志,1996,16：95-97
[69]王辰,杜敏捷,等.慢性肺源性心脏病急性发作期肺细小动脉血栓形成的病理观察[J].中华医学杂志,1997,77(2)：123
[70]孙妮娜,韩伟忠,等.雾化吸入低分子肝素对慢性阻塞性肺疾病大鼠等血栓前状态干预的实 研究[J].国际呼吸杂志,2008,
[2]陈丕仁,崔力,候加法,等.慢性阻塞性肺病动物模型的研究进展[J].中国实验动物学报,2007,15(3)：238-242
[3]Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic of obstructive pulmonary disease (COPD) [J].Eur Respir,1995,8:1398-1420
[4]Setoguchi Y, Tamaki Y, Oki M, et al. Transfer of endothelial nitric oxide synthase gene in the purpose of gene therpy. Nippon Rinsho,1996,54:369-376
[5]Janssens SP, Shimouchi A, Quetermous T, et al. Cloning and expression of a cDNA encoding human endothelial-derived relaxing factor/nitric oxide synthase. J Biol Chem,1992,267:14519-14522
[6]Boughton-Smith NK, Hutcheson IR, Deakin AM, et al. Protective effect of S-nitroso-N-acetyl-peniillamine in endotoxin-induced acute intestinal damage in the rats. EUR J Pharmacol.1990, Dec 4,191(3):484-488
[7]Chu A, Chsmbers DE, Lin CC, et al. Effects of inhibition of nitric oxide formation on basal vasomotion and endothelium-dependent responses of coronary arteries in awake dog. J Clin Invest,1991, Jun,87:1964-1968
[8]Bassenge E, ric Antiplatelet effects of endotheliud-deried relaxing factor and nitric oxide donors. Eur Heart J,1991,12
[9]Blau h,Riklis S,Vanlarden JF, et al. Nitric oxide production by ratalveolar macrophages can be modulated invitro by surfanctant protein A. Am Jphsiol,1997,292(6): 1198-1204
[10]Wright JL,Churg A. Animal models of cigarette smoke-induced COPD[J]. Chest,2002, 122:301-306.
[11]金焱,庞宝森,武维屏,等.一种实验性大鼠慢性阻塞性肺疾病模型的建立.心肺血管病杂志,2004,239(3)：179-181
[12]马楠,崔德建,梁延杰,等.气管内注入脂多糖法建立大鼠慢性支气管炎模型.中华结核和呼吸杂志,1996,22(6)：371-372
[13]宋一平,崔德健,茅培英,等.慢性阻塞性肺病大鼠模型的建立及药物干预的影响[J].军医进修学院学报,2001,22：99-102
[14]Tavares JL, Wangoo A, Dilworth P, et al.Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages[J]. Respir Med,1997,91:31-39.
[15]Brosnan CF, Cannella B, Battbtini L, et al. Cytokine localization in multiple sclerosis lesions:correlation with adhesion molecule expression and reactive nitrogen species[J]. Neurology,2005,45(6):S1-S21.
[16]S0, Novotny JR, Wicks IP, et al.The role of the LFA-1 ICAM-1 interaction in human leukocyte homing and adhesion.Immunol Rev,1989,108:135
[17]Tosi MF, Stark JM, Smith CW, et al. Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines:Effects on neutrophil epithelial cell adhesion[J].Am J Respir Cell Mol Biol,1992,7:214-221
[18]Vignola AM, Campbell AM, Chanez P, et al. HLA-DR an d ICAM-1 expression on bronchial epithelial cells in asthma and chronic bronchitis [J]. Am Rev Respir Dis,1993; 148(3): 689.
[19]Stefano AD, Maestrelli P, Roggeri A, et al. Upregulat ion of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis [J]. Am J Respir Crit Care Med,1994;149(3):803.
[20]曾春芳,吴亚梅.细胞粘附分子在慢性阻塞性肺疾病大鼠气道炎症中的作用[J],重庆医科大学学报,2004,29(5)：644-647
[21]Steve K, Springer T, Schmalstieg F, et al. Defective Natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency[J].J Immunol,1984,133:2972-2980
[22]HACIEVLIYAGIL SS, GUNEN H,MUTLU LC, et al. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease[J]. RespirMed,2006,100(5):846-54
[23]RAHMAN MS, YANG J, LIAN YS, et al. IL-17R activation of human airway smooth muscle cells induces CXCL-8 production via a transcrip tional-dependent mechanism. Clinical Immunology[J],2005,115(1):268-276
[24]Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med,1998,338:436-445
[25]Masubuchi T, Koyama S, Sato E, et al. Smoke extract stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Pathol,1998,153:1903-1912.
[26]Gunn MD, Nelken NA, Liao X, et al. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgeniec mice but requires an additional stimulus for inflammatory activation. J Immunol,1997,158:376-383
[27]Hautamaki RD, Kobayashi DK, Senior RM, et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science,1997,277:2002-2004
[28]Traves SL, Culpltt SV. Russell RE, et al. Increased levels of the chemokines GRO alpha and MCP-1 in sputum samples from patients with COPD. Thorax,2002; 57(7):590.
[29]王慧,程德云,关键,等.单核细胞趋化蛋白—1与COPD大鼠气道炎症的研究[J].四川大学学报,2004,35(5)：634-637
[30]Zhang K, Mehrnaz GK, Michael LT, et al. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-indueed pulmonary fibrosis. J Immunol,1994,153; 4733-4741
[31]Chowers Y, Lider 0, Schor H, et al. Charaterization of protein of Z-dependent protease inhibitor[J]. Blood,2000,96:3049-3051
[32]Dowing LJ,Strieter RM, Kadell AM, et al. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis[J].Jvasc Surg,1998,28(5):848-854
[33]Lever R, Hoult JR, Page CP. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro[J].Br J Pharmacol,2000,129(3):533-540
[34]Wan MX, Zhang XW, Torkvist L, et al. Low molecular weight hearin inhibits tumor necrosis factor alphainduced leukocyte rolling[J]. Inflamm Res,2001,50(12):581-584
[35]Deventer S JH. Tumor necrosis factor and Crohn's disease [J].Gut 1997,40:443-448
[36]韩红,夏冰,刘君炎.低分子肝素对三硝基苯磺酸诱发大鼠结肠炎肿瘤坏死因子α、CD62P的影响[J].中华消化杂志,2003,23(7)：418-420
[37]Manduteanu I.Voinea M, Capraru M, et al.A novel attribute of enxaparin:inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules[J]. Pharmacology.2002,65(1):32-37
[38]韩秀珍,焦波,尚雪原,等.低分子肝素对白细胞粘附和粘附分子表达的影响[J].中国生化药物杂志,2003,24(4)：179-181
[39]Jones H, Paul W, Page CP. The efects of heparin and related molecules on vascular pemeability and neutrophil accumulation in rabbit skin[J]. Br J Humncol,2002,135(2): 469-479
[40]李介秋,张开诚,吕新生,等.低分子量肝素治疗急性出血坏死性胰腺炎的实验研究[J].国普通外科杂志,2000,9(3)：234-236.
[41]张估,贻璞,李美花,等.低分子肝素对肾小球系膜细胞及细胞外基质作用的研究[J].中华肾脏病杂志,2001,17(1)：27-30.
[42]刘雷,孟建中.细胞间黏附分子-1在移植肾缺血再灌注损伤中的作用[J].国际移植与血液净化杂志,2006,4(2)12-14
[43]宋一平,崔德健,茅培英,等.慢性阻塞性肺病大鼠模型的建立及药物干预的影响[J].军医进修学院学报,2001,22：99-102
[44]程兆忠,徐晟伟,韩伟忠.氨溴索对慢性阻塞性肺疾病大鼠模型肺的保护作用[J].青岛大学医学院学报,2004,40(2)：101-106
[45]RACHEL A,BROWN, LUIGI A. Additional clinical benefit of enoxaparin in COPD patients receiving Salmeterol and fluticasone propionate in combination[ J]. Pulmonary Pharmacology Theraperties,2006,19(6):419-424
[1]GOLD Executive Committee[DB/OL]. Guidelines:Global Strategy for Diagnosis, Management, andr Prevention of COPD, Noverber2006[2006-11-18].
[2]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版).中华结核和呼吸杂志.2007,30：7-16
[3]程显声,李景周,张珍祥,等.慢性阻塞性肺疾病、肺心病人群防治的研究基线资料分析.中华结核和呼吸杂志,1998,121：749-752
[4]Stolk J. Rodolphus A, Dasies el al. [J] Pathol,1992,349-356
[5]Meshi B, Vitalis TZ, Ionescu D, et al. Emphysematous lung destruction by cigarette smoke The effects of latent adenoviral infection on the lung inflammatiory response [J]Am J Respir Cell M-ol Biol,2002,26(1):52-57.
[6]Retamales I, Elliot WM, Meshi B, et al. Ampification inflammation in Emphysema and its association with latent adenoviral infection [J].Am J Respir Crit Care Med,2001,164:469-473.
[7]Hertzen LCV. Chlamydia Pneumoniae and its role in chronic obstructive Pulmonary disease [J].Ann Med.1998,30:27-37.
[8]马楠.粘附分子及细胞因子在慢性阻塞性肺疾病中的作用[J].国外医学呼吸系统分册,1998,18：57-5
[9]Di Stefano A, Capelli A, lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med,1998, 158:1277-1285
[10]Majo J, Ghezzo H, Cosia MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J,2001,17:946-953.
[11]Jeffrey PK. Structural and inflammatory changes in COPD:a comparison with asthma Thorax,1998,53:129-136
[12]Finkelstein R. Fraser RS, Ghezzo H, et al. Alveolar inflammtion and its relationship to emphysema in smokers. Am J Respir Crit Care Med.1995,152:1666-1672
[13]Selman M, Montano M. Ramos L, et al. Tobaccosmoke induced lung emphysema. Am J Physiol,1996,211:734-743
[14]Finlay GA. O Driscoll LR. Russetl KJ. et al. Matrix metalloproteinase ex-pression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med,1997.156: 240-247
[15]Huninghake GW.Crystal RG Cigarette smoking and lung destruction:accumulation of neutrophils in the lung of cigarette smokers. Am Rev Respir Dis,1983,128:833-838
[16]Martin TR, Ganesh R. Manunder RJ, et al. The effects of chonic bronchitis and chronic air flow obstruction on lung cell populations recovered by bronchoalveolar lavage. Am Rev Respir Dis.1985,135:254-260
[17]Huinghake GW, Gadek JE, Kawanami 0, et al. Inflammatory and immune process in the human lung in health and disease evaluation by bronchoaveolar lavage. Am J Pathol,1979,97:149-206
[18]Lourdes SV. Annie P. Miguel G, et al. Up regulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell in COPD. Chest.2000.117:684-693
[19]Angshu B, Terence A R Seemungal. Raymond J Sapsford. et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations、 Thorax,2000,55:11-120
[20]Pi Stefawo A. Capelli A. Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med,1998,158:1277-1285
[21]Turato G, Zuin R, Saetta M. Pathogenesis and pathology of COPD. Respiration,2001, 68:117-128
[22]Zeid NA, Muller HK. Tobacco smoke induced lung granulomas and tumors:association with pulmonary langerhans cells. Pathology,1995, Z7:247-254
[23]D Hulst AI,Vermeulen KY,Brusselle GG,et al.Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J,2005,26:204-213
[23]Patel IS, Roberts NJ, Lloyd-Owen SJ, et al. Airway epithelial inflammatory responses and clinical parameters in COPD. Eur Respir J,2003,22:94-99
[24]Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med,1996,153:530-534
[25]W outers EF. Locgl and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc,2005,2:26-33
[26]Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbatIons [J]. Thorax,2000,55(2): 114-120
[27]Beeh KM, Kornmann O, Buhl R, et al. Neutrophil chemotactic activity of sputum from patients with COPD:role of interleukin 8 and leukotriene B4. Chest,2003,123:1240-1247.
[28]de Boer WI, Sont JK, van Schadewijk A, et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol,2000,190:619-626
[29]HACIEVLIYAGIL SS,GUNEN H,MUTLU LC, et al. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease[J]. RespirMed,2006,100(5):846-54
[30]RAHMAN MS, YANG J, LIAN YS, et al. IL-17R activation of human airway smooth muscle cells induces CXCL-8 production via a transcrip tional-dependent mechanism. Clinical Immunology[J],2005,115(1):268-276
[31]Sandford AJ, Chagani T, Weir TD, et al. Susceptibility genes for rapid deline of lung function in the lung heath study. AM j Respir Cric Care Med,2001, 163(2):469-473
[32]揭志军,杨文兰,蔡映云.α1-抗胰蛋白酶临床应用的前景.国外医学呼吸系统分册,1999,19(4)：192
[33]Kasielski M, Nowak D. Longterm administration of Nacetylcystinedecreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease [J]. Respir Med,2001,95:448-456
[34]Macnee W, Donaldson K. Exacerbations of COPD:environmental mechanisms. Chest, 2000;117:303s-317s
[35]Rahman I, M ulier B, Gilm our PS, et al. Oxidant-mediated lung epithelial cell tolerance:the role of intracellular glutathione and nuclear factor-kappaB. Biochem pharma,2001;62:787-794
[36]SHI M M, Chong I, Godleski JJ, et al. Regulation of macrophage inflammatory protein-2 gene expression by oxidative stress in rat alveolar macrophages. Im munology,1999; 97:309-315
[37]Salvatore C, Emanuela M, Laura D, et al. Protective effects of N-acetylcysteine on lung injury and red blood cell modification induced by carrageenan in the rat. FASEB J,2001;15:1187-1200
[38]Blames J, Beeklake M, Blanc P, et al. American thoracic society statement:occupational contribution to burden of airway disease. Am J Respir Crit Care Med,2003,167:787-797
[39]张嫒.吸入糖皮质激素和长效B2受体激动剂治疗支气管哮喘及慢性阻塞性肺疾病[J].临床荟萃,2005,20(6)：357-359
[40]Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapyimproves outcomes of exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004 69:1298-1303
[41]Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oralprednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med,2003,348:2618-2625
[42]Ohbayashi H. Novel neutrophil elastase inhibitors as a t reatment for neut rophil-predominant inflammatory lung diseases. Drugs,2002,5 (9):910-923
[43]Kuraki T, Ishibashi M, Takayama M, et al. A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rat s. Am J Respir Crit Care Med,2002,166 (4):496-500
[44]Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage mediated elastolysis roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol,2002,283 (4):L867-873
[45]Barnett WE. Improved anticoagulant substance[P]. WO 81/03276.1981
[46]Bianchini P. Process for preparation of oligosaccharide fractions by degradation of heparin[P]. US 4629699,1986.
[47]Nielson JI. Process of using tight absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin[P]. US 5106734,1992.
[48]Sundaram M, Qi Y, Shriver Z, et al. Rational design of low molecular weight heparins with improved in vivo activity[J]. PNAS,2003,100:651-656
[49]Bergonzini G. Oligo-Heparin Action on Endogenous Glycosaminoglycans. Pharmacokinetics:Direct and Mediated Effects[J]. Semin Thromb Hemost,1994,20(3):274.
[50]曹苹,张麟生.低分子肝素的抗凝与抗血栓作用[J].中国医院药学杂志,2001,21(5)：91.
[51]林平,林英,王晓红.低分子肝素[J].临床军医杂志,2006,34(5)：630-632
[52]Dowing LJ,Strieter RM,Kadell AM, et al. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis[J]. Jvasc Surg,1998,28(5):848-854
[53]韩秀珍,焦波,尚雪原,等.低分子肝素对白细胞粘附和粘附分子表达的影响[J].中国生化药物杂志,2003,24(4)：179-181
[54]Manduteanu I, Voinea M, Capraru M, et al.A novel attribute of enxaparin:inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules[J].Pharmacology.2002,65(1):32-37
[55]Mcbride WT, Armstrong MA, Mcmurray TJ. An investigation of the efectsHeparin, low molecular weight heparin, protamine, and fentany on the balance of pro-and anti-inflammatory cytoinesin in-vitro monocyte culturesl[J]. Anaesthesia,1996,51:635-640
[56]张佶,张贻璞,李美花,等.低分子肝素对肾小球系膜细胞及细胞外机制作用的研究[J].中华肾脏杂志,2001.17：27-29
[57]Gambaro G, Cavzzana A D. Luzi P, et al. Glylosaminoglycans morphological renal alterations and albuminuria in diabetic rats [J]. Kidney Int,1992,42:285-287
[58]Pross M, Lippert H, Nester G, et al. Effect of low molecular weight heparin on intra-abdominal metastasis in a lapavoscopic experinental study[J]. Int J Colorectal Dis,2004,19:143-146
[59]汪昱,郑起,闰均,等.低分子肝素对肝癌生长和转移抑制作用的研究[J].中华普通外科杂志,2004,19：758-760
[60]Deeps P R, Varalakshmi P. Protective efects of certopar in sodium, a low molecular weight heparin derivative, inexperimental atherosclerosis[J]. Clinchim Acta,2004, 339:105-115
[61]se Pattems of Low-Molecular Weight Heparin and the Impact on Length of Stay in Patients Hospitalized for Atrial Fibrillation。Am Heart J 145 (4):665-669,2003
[62]叶妮,张临洪.低分子肝素的药理作用及其在缺血性脑卒中的临床应用.国外医学-脑血管疾病分册.2001,9(1)：45-48
[63]吴蕙民,等.低分子肝索治疗进展型缺血性脑卒中(脑血栓)的临床研究.浙江临床医学,2001,3(1)17-18
[64]薛玉文,王均玲,杜以明,等.肝素与低分子肝素对急性肺栓塞抗凝治疗作用的比较.新医学,2005,36(3)：149-150
[65]杜鹃.慢性肺心病患者血浆α—颗粒膜蛋白及D—二聚体的变化.贵州医药,2001,25：401-402
[66]NenciGG, Berrettini M, Todiso T, Parise P. Enhanced plasma beta-thrombobloolobulin in hypoxaemia:effects of dipyridamole. N Engl J Med 1981(letter),304:1044
[67]Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Corsova C, and Chronic Obstructive bronchitis Hasemostasis G roup. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Haemost 1994,72:343-446
[68]马瑞,王少媛.慢性阻塞性肺疾病和慢性肺心病的血栓前状态研究[J].中华结核和呼吸杂志,1996,16：95-97
[69]王辰,杜敏捷,等.慢性肺源性心脏病急性发作期肺细小动脉血栓形成的病理观察[J].中华医学杂志,1997,77(2)：123
[70]孙妮娜,韩伟忠,等.雾化吸入低分子肝素对慢性阻塞性肺疾病大鼠等血栓前状态干预的实 研究[J].国际呼吸杂志,2008,